美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

220.54

-17.9700-7.53%

盤後：220.37-0.1700-0.08%19:56 EDT

成交量：70.03萬

成交額：1.55億

市值：237.16億

市盈率：-36.01

高：235.03

開：220.15

低：214.12

收：238.51

資料載入中...

總覽公司新聞公告

百濟神州4月7日成交額為1.55億美元

BeiGene(ONC.US)獲加拿大皇家銀行首次覆蓋，給予優於大市評級, 目標價312.00美元。

百濟神州：將於2025年5月21日召開2025年年度股東大會

百濟神州4月4日成交額為1.63億美元

百濟神州終止TIGIT抗體歐司珀利單抗肺癌治療臨牀開發計劃已累計投入超20億元

每日经济新闻

療效難達預期，百濟神州終止歐司珀利單抗肺癌3期臨牀試驗

百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop

百濟神州04月03日繼續上漲，股價創歷史新高

同花顺AI资讯社

百濟神州4月2日成交額為2.02億美元

百濟神州4月1日成交額為2.49億美元

【港股早評：三大指數低開生物醫藥股集體回調機器人概念股活躍】隔夜美股三大指數漲跌不一，中概指數漲0.5%。昨日反彈的的港股小幅低開，恒指跌0.17%，國指跌0.25%，恒生科技指數跌0.16%。盤面上，大型科技股漲跌各異總體波動不大，網易、百度、騰訊飄紅，安徽SU7事故持續發酵，昨日大跌的小米續跌1%，阿里巴巴、美團小幅下跌；昨日大幅上漲的生物醫藥股集體回調，藥明繫個股跌幅明顯，藥明合聯跌6.5%，百濟神州跌4%；內銀股、蘋果概念股、汽車股、煤炭股多數走低，昨日飆漲19%創新高的老鋪黃金跌近4%。另一方面，機器人概念股多數表現強勢，速騰聚創大漲7.5%，優必選漲2.5%，濠賭股、餐飲股部分上漲，美高梅中國、百勝中國漲超2%。

百濟神州(06160)因受限制股份單位獲歸屬發行37.64萬股

A股創新藥概念探底回升，聖諾生物漲停，翰宇藥業、百濟神州、海正藥業、百花醫藥等跟漲。

百濟神州(06160)因受限制股份單位獲歸屬發行16.87萬股

百濟神州淨虧6.45億美元，剛遭高瓴減持，套現或超50億港元

读创客户端

百濟神州3月28日成交額為1.38億美元

澤布替尼大賣26億美元，百濟神州虧損進一步收窄

国际金融报

財報解讀丨虧損收窄26.9%，研發燒錢19.5億，百濟神州的盈利困局如何破？

美股研究社

百濟神州(ONC)盤前漲超2% 2024年收入同比增長55.0%

百濟神州，澤布替尼單核帶隊能到多高

证券市场周刊

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":220.54,"timestamp":1744056000000,"preClose":238.51,"halted":0,"volume":700295,"hourTrading":{"tag":"盘后","latestPrice":220.37,"preClose":220.54,"latestTime":"19:56 EDT","volume":495,"amount":108694.62,"timestamp":1744070180169},"delay":0,"floatShares":74326060,"shares":107535059,"eps":-6.124009,"marketStatus":"未開盤","change":-17.97,"latestTime":"04-07 16:00:00 EDT","open":220.15,"high":235.03,"low":214.1224,"amount":154813326.27535,"amplitude":0.087659,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-6.124009,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1744099200000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":238.51,"preHourTrading":{"tag":"盘前","latestPrice":220,"preClose":238.51,"latestTime":"09:29 EDT","volume":3027,"amount":709096.99845,"timestamp":1744032599909},"postHourTrading":{"tag":"盘后","latestPrice":220.37,"preClose":220.54,"latestTime":"19:56 EDT","volume":495,"amount":108694.62,"timestamp":1744070180169},"volumeRatio":1.079728,"impliedVol":0.6809,"impliedVolPercentile":0.9846},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":74326060,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":1.079728,"shares":107535059,"dividePrice":0,"high":235.03,"amplitude":0.087659,"preClose":238.51,"low":214.1224,"week52Low":126.9681,"pbRate":"7.12","psRate":"6.22","week52High":287.88,"institutionHeld":0,"latestPrice":220.54,"eps":-6.124009,"divideRate":0,"volume":700295,"delay":0,"ttmEps":-6.124009,"open":220.15,"prevYearClose":184.71,"prevWeekClose":238.51,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":272.17,"twentyDayClose":242.66,"sixtyDayClose":177.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525488650","title":"百濟神州4月7日成交額為1.55億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525488650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525488650?lang=zh_tw&edition=fundamental","pubTime":"2025-04-08 10:10","pubTimestamp":1744078241,"startTime":"0","endTime":"0","summary":"美东时间2025年4月7日，百济神州成交额为1.55亿美元，成交额较昨日减少4.99%，当日成交量为70.03万股。百济神州于2025年4月7日跌7.53%，报220.54美元，该股过去5个交易日跌18.97%，年初至今涨19.4%，过去60日涨23.98%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250408101044a451ac5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250408101044a451ac5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2525402802","title":"BeiGene(ONC.US)獲加拿大皇家銀行首次覆蓋，給予優於大市評級, 目標價312.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2525402802","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525402802?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 23:03","pubTimestamp":1744038193,"startTime":"0","endTime":"0","summary":"BeiGene(ONC.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价312.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/07230349360634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2525401265","title":"百濟神州：將於2025年5月21日召開2025年年度股東大會","url":"https://stock-news.laohu8.com/highlight/detail?id=2525401265","media":"公司公告","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525401265?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 19:40","pubTimestamp":1744026059,"startTime":"0","endTime":"0","summary":"百济神州公告，公司将于2025年5月21日召开年度股东大会，会议将采用现场投票、邮寄投票（仅限非A股股东）和网络投票相结合的方式。会议地点位于开曼群岛，网络投票通过上海证券交易所股东大会网络投票系统进行。会议将审议包括重选董事、批准独立审计师及授权董事会发行股份等12项议案。涉及融资融券、转融通业务的相关账户需按照监管指引执行投票程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407195046a450e254&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250407195046a450e254&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK4139","ONC"],"gpt_icon":0},{"id":"2525676393","title":"百濟神州4月4日成交額為1.63億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525676393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525676393?lang=zh_tw&edition=fundamental","pubTime":"2025-04-05 10:07","pubTimestamp":1743818876,"startTime":"0","endTime":"0","summary":"美东时间2025年4月4日，百济神州成交额为1.63亿美元，成交额较昨日增加57.72%，当日成交量为67.53万股。百济神州于2025年4月4日跌9.76%，报238.51美元，该股过去5个交易日跌10.8%，年初至今涨29.13%，过去60日涨36.21%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405100805a44e6ac7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405100805a44e6ac7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2524229551","title":"百濟神州終止TIGIT抗體歐司珀利單抗肺癌治療臨牀開發計劃 已累計投入超20億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524229551","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524229551?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 11:53","pubTimestamp":1743738808,"startTime":"0","endTime":"0","summary":"每经记者 林姿辰    每经编辑 文多4月3日，百济神州宣布停止TIGIT抗体Ociperlimab作为肺癌潜在治疗方法的临床开发计划。截至2024年12月，欧司珀利单抗开发项目已入组2000多例患者。截至2024年上半年末，百济神州已在欧司珀利单抗项目累计投入20.90亿元。据报道，因针对肺癌的数项Ⅲ期临床试验未达到预期效果，罗氏制药公司在2024年年报中宣布终止部分TIGIT抗体相关临床试验，仅保留肝癌适应症的临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040411541094cbb900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040411541094cbb900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","ONC","688235"],"gpt_icon":0},{"id":"2524698862","title":"療效難達預期，百濟神州終止歐司珀利單抗肺癌3期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2524698862","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524698862?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 22:25","pubTimestamp":1743690353,"startTime":"0","endTime":"0","summary":"本文来源：时代财经4月3日，百济神州宣布终止TIGIT抗体BGB-A1217（欧司珀利单抗）作为肺癌潜在治疗方法的临床开发项目。百济神州表示，依据预先计划的无效性分析结果，独立数据监查委员会建议终止正在进行的3期AdvanTIG-302试验（NCTO4746924）。试验的总体有效性和安全性数据评估表明，该研究或难以达到总生存期主要终点。但同时，未发现新的安全信号。经慎重考虑，公司决定终止该试验。BGB-A1217是一种针对TIGIT的在研人源化IgG1变体单克隆抗体，此前有两项针对非小细胞癌的三期临床在推进。（时代财经 杜苏敏）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040322274194cb36c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040322274194cb36c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4139","06160","ONC"],"gpt_icon":0},{"id":"2524521263","title":"百濟神州在肺癌試驗失敗後放棄TIGIT抗體BeiGene abandons TIGIT antibody after lung cancer flop","url":"https://stock-news.laohu8.com/highlight/detail?id=2524521263","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524521263?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 21:49","pubTimestamp":1743688140,"startTime":"0","endTime":"0","summary":"BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.百济神州决定停止开发其靶向TIGIT的药物ociperlimab，这是该药物类别遭遇的又一次挫折。TIGITTIGITin particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody特别是被证明是药物开发人员的一个棘手目标，而百济神州的决定是在默克公司放弃其抗TIGIT抗体开发的几个月后做出的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040321501594cb2fbe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","06160","ONC"],"gpt_icon":0},{"id":"2524286893","title":"百濟神州04月03日繼續上漲，股價創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2524286893","media":"同花顺AI资讯社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524286893?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 16:00","pubTimestamp":1743667215,"startTime":"0","endTime":"0","summary":"04月03日，百济神州股价继续上涨。截至今日收盘，百济神州上涨1.04%，收盘价为250.78元，盘中股价最高触及254.77元，股价创历史新高。百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽、百泽安、帕米帕利。近一年公司股价累计上涨99.63%，同期沪深300指数上涨8.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403160602a6ae386f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403160602a6ae386f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","06160","LU1969619763.USD","ONC","BK1588","BK1500","LU0588546209.SGD","BK1161","688235","LU0307460666.USD","BK1583"],"gpt_icon":0},{"id":"2524475535","title":"百濟神州4月2日成交額為2.02億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524475535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524475535?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 10:10","pubTimestamp":1743646212,"startTime":"0","endTime":"0","summary":"美东时间2025年4月2日，百济神州成交额为2.02亿美元，成交额较昨日减少19.17%，当日成交量为73.73万股。百济神州于2025年4月2日涨1.38%，报274.78美元，该股过去5个交易日涨9.51%，年初至今涨48.76%，过去60日涨51.96%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403101023a44c041b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403101023a44c041b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2524570109","title":"百濟神州4月1日成交額為2.49億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524570109","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524570109?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 10:09","pubTimestamp":1743559745,"startTime":"0","endTime":"0","summary":"美东时间2025年4月1日，百济神州成交额为2.49亿美元，成交额较昨日增加72.50%，当日成交量为90.55万股。百济神州于2025年4月1日跌0.42%，报271.04美元，该股过去5个交易日涨8.21%，年初至今涨46.74%，过去60日涨47.3%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402100913a6ac9c5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402100913a6ac9c5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2524817776","title":"【港股早評：三大指數低開 生物醫藥股集體回調 機器人概念股活躍】隔夜美股三大指數漲跌不一，中概指數漲0.5%。昨日反彈的的港股小幅低開，恒指跌0.17%，國指跌0.25%，恒生科技指數跌0.16%。盤面上，大型科技股漲跌各異總體波動不大，網易、百度、騰訊飄紅，安徽SU7事故持續發酵，昨日大跌的小米續跌1%，阿里巴巴、美團小幅下跌；昨日大幅上漲的生物醫藥股集體回調，藥明繫個股跌幅明顯，藥明合聯跌6.5%，百濟神州跌4%；內銀股、蘋果概念股、汽車股、煤炭股多數走低，昨日飆漲19%創新高的老鋪黃金跌近4%。另一方面，機器人概念股多數表現強勢，速騰聚創大漲7.5%，優必選漲2.5%，濠賭股、餐飲股部分上漲，美高梅中國、百勝中國漲超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2524817776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524817776?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 09:29","pubTimestamp":1743557343,"startTime":"0","endTime":"0","summary":"隔夜美股三大指数涨跌不一，中概指数涨0.5%。昨日反弹的的港股小幅低开，恒指跌0.17%，国指跌0.25%，恒生科技指数跌0.16%。盘面上，大型科技股涨跌各异总体波动不大，网易、百度、腾讯飘红，安徽SU7事故持续发酵，昨日大跌的小米续跌1%，阿里巴巴、美团小幅下跌；昨日大幅上涨的生物医药股集体回调，药明系个股跌幅明显，药明合联跌6.5%，百济神州跌4%；内银股、苹果概念股、汽车股、煤炭股多数走低，昨日飙涨19%创新高的老铺黄金跌近4%。另一方面，机器人概念股多数表现强势，速腾聚创大涨7.5%，优必选涨2.5%，濠赌股、餐饮股部分上涨，美高梅中国、百胜中国涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/02092949235396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["513600","ONC","TTTN","09987","YANG","08496","HXXD.SI","BK1531","YUMC","HSCEI","06160","LU0054450605.USD","81810","02498","09880","LU0214875030.USD","02833","NTES","03086","399441","HSTECH","MCHmain","80700","02282","02268","161726","LU0708995583.HKD","HSI","LU0287142896.SGD","09999","HMTD.SI","SG9999006597.SGD","161032","HHImain","LU1251922891.USD","HTCD.SI","688235"],"gpt_icon":0},{"id":"2524900806","title":"百濟神州(06160)因受限制股份單位獲歸屬發行37.64萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2524900806","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524900806?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 08:39","pubTimestamp":1743467958,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年3月31日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行37.64万股。于2025年3月31日，因购股权获行使发行合计185.13万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1272287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4139","LU1969619763.USD","BK1500","BK1583","BK1161","688235","ONC","LU0307460666.USD","06160","LU2328871848.SGD","BK0239","LU0588546209.SGD"],"gpt_icon":0},{"id":"2523305249","title":"A股創新藥概念探底回升，聖諾生物漲停，翰宇藥業、百濟神州、海正藥業、百花醫藥等跟漲。","url":"https://stock-news.laohu8.com/highlight/detail?id=2523305249","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523305249?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 10:09","pubTimestamp":1743386968,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0102","688235","BK0070","ONC","BK0216","BK1161","300199","06978","BK4139","BK1500","BK1583","LU0588546209.SGD","BK0188","600721","06160","159992","159982","BK1574","BK0028","LU2328871848.SGD","BK0077","399300","LU0307460666.USD","600267","BK0060","LU1969619763.USD","688117","BK0239","BK1588"],"gpt_icon":0},{"id":"2523893316","title":"百濟神州(06160)因受限制股份單位獲歸屬發行16.87萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2523893316","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523893316?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 08:13","pubTimestamp":1743379994,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年3月28日，因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行16.87万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1271264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","BK1588","BK0239","BK1500","LU0588546209.SGD","BK1161","LU1969619763.USD","688235","ONC","06160","BK1583","LU2328871848.SGD","BK4139"],"gpt_icon":0},{"id":"2523627984","title":"百濟神州淨虧6.45億美元，剛遭高瓴減持，套現或超50億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523627984","media":"读创客户端","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523627984?lang=zh_tw&edition=fundamental","pubTime":"2025-03-30 16:02","pubTimestamp":1743321731,"startTime":"0","endTime":"0","summary":"财报显示，百济神州2024年营收同比增长约55%至约38亿美元，其中产品收入增长约72.6%至约38亿美元。亏损进一步收窄约26.9%至约6.45亿美元。然而，百济神州一直处于亏损状态，2017年至2020年，公司净利润亏损9.82亿元、47.47亿元、69.15亿元和113.84亿元。2021年至2023年，百济神州净利润分别亏损97.48亿元、136.42亿元和67.16亿元。总体来看，八年时间，百济神州净利润累计亏损591.12亿元，日均亏损超过2000万元。以当时的收盘价计算，高瓴可能套现50亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033016032594c5fd2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033016032594c5fd2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2523651140","title":"百濟神州3月28日成交額為1.38億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523651140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523651140?lang=zh_tw&edition=fundamental","pubTime":"2025-03-29 10:05","pubTimestamp":1743213943,"startTime":"0","endTime":"0","summary":"美东时间2025年3月28日，百济神州成交额为1.38亿美元，成交额较昨日减少23.62%，当日成交量为51.46万股。百济神州于2025年3月28日涨1.82%，报267.39美元，该股过去5个交易日涨6.12%，年初至今涨44.76%，过去60日涨45.47%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329100549a44609af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329100549a44609af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2522579994","title":"澤布替尼大賣26億美元，百濟神州虧損進一步收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2522579994","media":"国际金融报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522579994?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 20:32","pubTimestamp":1743165150,"startTime":"0","endTime":"0","summary":"3月27日盘后，创新药明星公司百济神州发布2024年全年业绩公告。亏损进一步收窄约26.9%至6.45亿美元。泽布替尼大卖26亿美元具体来看，2024年为百济神州业绩“回血”的依然是第二代BTK抑制剂泽布替尼。2024年全年伊布替尼全球销售额33.47亿美元，同比下滑6.9%。除了同艾伯维的诉讼外，百济神州去年11月还就一项诉讼案达成和解，同样事关百悦泽的专利。截至2024年年底，百济神州现金流达26亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328203518a6a777ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328203518a6a777ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2522049575","title":"財報解讀丨虧損收窄26.9%，研發燒錢19.5億，百濟神州的盈利困局如何破？","url":"https://stock-news.laohu8.com/highlight/detail?id=2522049575","media":"美股研究社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522049575?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 20:03","pubTimestamp":1743163380,"startTime":"0","endTime":"0","summary":"营收增速超行业水平，创新药成增长引擎财报显示，百济神州2024年营收为38.1亿美元，较上年同期的24.59亿美元增长55%。尽管收入高增，公司全年研发费用仍高达19.53亿美元，持续加码血液瘤、实体瘤及双抗等前沿领域。而百济神州亏损收窄26.9%背后：财报显示，2024年，百济神州净亏损6.45亿美元，同比收窄26.9%，非GAAP经营利润首次转正。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328201536a6a7723a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328201536a6a7723a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2522524905","title":"百濟神州(ONC)盤前漲超2% 2024年收入同比增長55.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522524905","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522524905?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 18:40","pubTimestamp":1743158458,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨超2%，截至发稿，报269.59美元。消息面上，百济神州公布，截至2024年12月31日止年度的收入合计较上年度增加约14亿美元或约55.0%至约38亿美元。产品收入较上年度增加约16亿美元或约72.6%至约38亿美元。百悦泽在2024年全年的全球收入达到26亿美元，较上年相比增长104.9%。截至2024年12月31日止年度的净亏损较上年度减少约2.37百万美元或约26.9%至约6.45百万美元。经调整后(即不包括该加速折旧)，截至2024年12月31日止年度，产品销售毛利率从上年同期的83.2%上升至85.5%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"286924","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","688235","LU0588546209.SGD","ONC","BK0239","06160","BK1583","BK4139","LU0307460666.USD","BK1588","LU2328871848.SGD","BK1161","BK1500"],"gpt_icon":0},{"id":"2522408065","title":"百濟神州，澤布替尼單核帶隊能到多高","url":"https://stock-news.laohu8.com/highlight/detail?id=2522408065","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522408065?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 17:11","pubTimestamp":1743153060,"startTime":"0","endTime":"0","summary":"　　现阶段，百济神州凭借泽布替尼有望实现盈利，如果最终能形成约15亿美元的营业利润，将把百济神州带到新的理想高度。　　利润端，百济神州2024年度归母净利润为亏损49.78亿元，上年同期为亏损67亿元。百济神州称， 2024年公司经调整的营业利润达5.28亿元，上年同期经调整的营业亏损为51.76亿元。　　据公告数据，2024年，百济神州产品收入为38亿美元，上年同期为22亿美元，这主要得益于泽布替尼的销售额增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-03-28/doc-inerfcmi9725079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1588","BK1500","BK1161","BK0239","LU1969619763.USD","BK1583","LU2328871848.SGD","06160","ONC","BK4139","LU0588546209.SGD","LU0307460666.USD","688235"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-14","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1747209600000,"name":null,"time":"","dateTimestamp":1747195200000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1741147200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-04","current":-44.082326,"percent":0.112903,"low":-46.072488,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"high":-22.805663,"avg":-34.459915,"sd":7.707641,"marketCap":28423666794},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794}],"updateTime":1744093269323}}}